Search Results - Geoffrey I Shapiro

  • Showing 1 - 17 results of 17
Refine Results
  1. 1

    Sensitizing HR-proficient cancers to PARP inhibitors by Elgene Lim, Shawn F. Johnson, Matthias Geyer, Violeta Serra, Geoffrey I. Shapiro

    Published in Molecular & Cellular Oncology (2017-11-01)
    Get full text
    Article


  2. 2

    STING agonism enhances anti-tumor immune responses and therapeutic efficacy of PARP inhibition in BRCA-associated breast cancer by Constantia Pantelidou, Heta Jadhav, Aditi Kothari, Renyan Liu, Gerburg M. Wulf, Jennifer L. Guerriero, Geoffrey I. Shapiro

    Published in npj Breast Cancer (2022-09-01)
    Get full text
    Article


  3. 3

    Exploring pharmacokinetics of talazoparib in ABCB1/ABCG2-deficient mice using a novel UHPLC-MS/MS method by Zahra Talebi, Dominique A. Garrison, Eric D. Eisenmann, Kalindi Parmar, Geoffrey I. Shapiro, Michelle A. Rudek, Alex Sparreboom, Yan Jin

    Published in Heliyon (2023-11-01)
    Get full text
    Article


  4. 4

    Phase I study of GC1008 (fresolimumab): a human anti-transforming growth factor-beta (TGFβ) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma... by John C Morris, Antoinette R Tan, Thomas E Olencki, Geoffrey I Shapiro, Bruce J Dezube, Michael Reiss, Frank J Hsu, Jay A Berzofsky, Donald P Lawrence

    Published in PLoS ONE (2014-01-01)
    Get full text
    Article


  5. 5

    982 Immune mediated mechanisms of PARPi resistance in BRCA1-associated triple negative breast cancer (TNBC) by Geoffrey I Shapiro, Anita Mehta, Jennifer L Guerriero, Adam Nelson, Patrice A Lee, Madisson Oliwa, Filipa Lynce, Nabihah Tayob, Madeline G Townsend, Kelly F Zheng, Nicholas A Saccomano

    Published in Journal for ImmunoTherapy of Cancer (2023-11-01)
    Article


  6. 6

    1111 Targeting lipid metabolism to improve PARP inhibitor response in BRCA-associated TNBC by Geoffrey I Shapiro, Jessica Thaxton, Anita Mehta, Jennifer L Guerriero, Adam Nelson, Carlos Wagner Wanderley, Filipa Lynce, Madeline G Townsend, Kelly F Zheng, Daniel E Michaud, Kiran Kurmi, Shakchhi Joshi, Marcia Haigis

    Published in Journal for ImmunoTherapy of Cancer (2023-11-01)
    Article


  7. 7

    RETRACTED ARTICLE: Polymerase θ inhibition activates the cGAS-STING pathway and cooperates with immune checkpoint blockade in models of BRCA-deficient cancer by Jeffrey Patterson-Fortin, Heta Jadhav, Constantia Pantelidou, Tin Phan, Carter Grochala, Anita K. Mehta, Jennifer L. Guerriero, Gerburg M. Wulf, Brian M. Wolpin, Ben Z. Stanger, Andrew J. Aguirre, James M. Cleary, Alan D. D’Andrea, Geoffrey I. Shapiro

    Published in Nature Communications (2023-03-01)
    Get full text
    Article


  8. 8

    Retraction Note: Polymerase θ inhibition activates the cGAS-STING pathway and cooperates with immune checkpoint blockade in models of BRCA-deficient cancer by Jeffrey Patterson-Fortin, Heta Jadhav, Constantia Pantelidou, Tin Phan, Carter Grochala, Anita K. Mehta, Jennifer L. Guerriero, Gerburg M. Wulf, Brian M. Wolpin, Ben Z. Stanger, Andrew J. Aguirre, James M. Cleary, Alan D. D’Andrea, Geoffrey I. Shapiro

    Published in Nature Communications (2023-12-01)
    Get full text
    Article


  9. 9

    MUC1-C dependency in drug resistant HR+/HER2− breast cancer identifies a new target for antibody-drug conjugate treatment by Ayako Nakashoji, Atrayee Bhattacharya, Hiroki Ozawa, Naoki Haratake, Keisuke Shigeta, Atsushi Fushimi, Nami Yamashita, Akira Matsui, Shoko Kure, Tomoe Kameyama, Makoto Takeuchi, Kazumasa Fukuda, Takamichi Yokoe, Aiko Nagayama, Tetsu Hayahsida, Yuko Kitagawa, Renyan Liu, Antonio Giordano, Rinath Jeselsohn, Geoffrey I. Shapiro, Donald Kufe

    Published in npj Breast Cancer (2025-04-01)
    Get full text
    Article


  10. 10

    Novel BRD2::NUTM1 Fusion in NUT Carcinoma With Exceptional Response to Chemotherapy: A Case Report by Sarah J. Wu, MD, PhD, Justin J. Kim, Yeying Huang, BS, R. Taylor Durall, BS, Simone Becker, RN, Stephanie Canty, CNP, MSN, Stefania Molinaro, BS, Evan Pisick, MD, Geoffrey I. Shapiro, MD, PhD, Christopher A. French, MD, Jia Luo, MD

    Published in JTO Clinical and Research Reports (2024-01-01)
    Get full text
    Article


  11. 11

    Cyclin D1 overexpression induces replication stress and microhomology-mediated end-joining dependence in mantle cell lymphoma by Jithma P. Abeykoon, Shuhei Asada, Guangli Zhu, Yuna Hirohashi, Lisa Moreau, Divya Iyer, Sirisha Mukkavalli, Kalindi Parmar, Gabriella Zambrano, Lige Jiang, Dongni Yi, Michelle Manske, Kimberly Gwin, Rebecca L. King, James R. Cerhan, Xiaosheng Wu, Zhenkun Lou, Geoffrey I. Shapiro, Thomas Witzig, Alan D’Andrea

    Published in The Journal of Clinical Investigation (2025-09-01)
    Get full text
    Article


  12. 12

    Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancer by Melinda L. Telli, Sara M. Tolaney, Geoffrey I. Shapiro, Mark Middleton, Simon R. Lord, Hendrik Tobias Arkenau, Andrew Tutt, Vandana Abramson, Emma Dean, Tufia C. Haddad, Robert Wesolowski, Jordi Ferrer-Playan, Thomas Goddemeier, Thomas Grombacher, Jennifer Dong, Patricia Fleuranceau-Morel, Ivan Diaz-Padilla, Ruth Plummer

    Published in npj Breast Cancer (2022-04-01)
    Get full text
    Article


  13. 13

    885 Characterization of the tumor microenvironment in advanced breast cancer patients treated with talazoparib followed by combination of talazoparib and avelumab by Edward T Richardson, Geoffrey I Shapiro, Jennifer L Guerriero, Claudine Isaacs, Filipa Lynce, Madeline G Townsend, Kelly F Zheng, Paula R Pohlmann, Kenichi Shimada, Arielle Heeke, Xue Geng, Candace Mainor, Mei Wei, Julie M Collins, Lauren M Sloat, Jane Staunton, Stuart J Schnitt, Joan S Brugge, Hongkun Wang

    Published in Journal for ImmunoTherapy of Cancer (2023-11-01)
    Article


  14. 14

    Phase I study of ribociclib (CDK4/6 inhibitor) with spartalizumab (PD-1 inhibitor) with and without fulvestrant in metastatic hormone receptor-positive breast cancer or advanced ov... by Sara M Tolaney, Tianyu Li, Elizabeth A Mittendorf, Geoffrey I Shapiro, Stephanie K Dougan, Nabihah Tayob, Joyce F Liu, Khanh Do, Heather Parsons, Molly DiLullo, Eileen Wrabel, Lestat R Ali, Ana C Garrido-Castro, Noah Graham, Christina Herold, Jennifer Desrosiers, Shom Goel, Amy J Williams

    Published in Journal for ImmunoTherapy of Cancer (2025-02-01)
    Get full text
    Article


  15. 15

    MAT2A inhibitor AG-270/S095033 in patients with advanced malignancies: a phase I trial by Mrinal Gounder, Melissa Johnson, Rebecca S. Heist, Geoffrey I. Shapiro, Sophie Postel-Vinay, Frederick H. Wilson, Elena Garralda, Gerburg Wulf, Caroline Almon, Salah Nabhan, Elia Aguado-Fraile, Peng He, Mathilde Romagnoli, Mohammad Hossain, Rohini Narayanaswamy, Amel Sadou-Dubourgnoux, Michael Cooper, Vasileios Askoxylakis, Howard A. Burris, Josep Tabernero

    Published in Nature Communications (2025-01-01)
    Get full text
    Article


  16. 16

    First-in-human phase I study of immunomodulatory E7046, an antagonist of PGE2-receptor E-type 4 (EP4), in patients with advanced cancers by Aurélien Marabelle, Aung Naing, Funda Meric-Bernstam, Xingfeng Bao, Andrea Varga, David S Hong, Aparna Parikh, Geoffrey I Shapiro, Özlem Ataman, Larisa Reyderman, Terri A Binder, Min Ren, Mingjie Liu, Satish Dayal, Amy Y Siu, Pallavi Sachdev, Lucy Xu, Vijay Bhagawati-Prasad, Ilian Tchakov, Chean Eng Ooi

    Published in Journal for ImmunoTherapy of Cancer (2020-05-01)
    Get full text
    Article


  17. 17

    Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers by James J. Harding, Sarina A. Piha-Paul, Ronak H. Shah, Jessica J. Murphy, James M. Cleary, Geoffrey I. Shapiro, David I. Quinn, Irene Braña, Victor Moreno, Mitesh Borad, Sherene Loi, Iben Spanggaard, Haeseong Park, James M. Ford, Mónica Arnedos, Salomon M. Stemmer, Christelle de la Fouchardiere, Christos Fountzilas, Jie Zhang, Daniel DiPrimeo, Casey Savin, S. Duygu Selcuklu, Michael F. Berger, Lisa D. Eli, Funda Meric-Bernstam, Komal Jhaveri, David B. Solit, Ghassan K. Abou-Alfa

    Published in Nature Communications (2023-02-01)
    Get full text
    Article


Search Tools: